Matches 301 - 350 out of 409 < 1 2 3 4 5 6 7 8 9 >


Match Document Document Title
US20170100465 METHOD OF TREATING DEPRESSION  
Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris,...
US20170100351 EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF  
Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition...
US20170095542 Reduction of Lipoma Tissue  
The amount of adipose tissue, including lipomas, at selected locations in the body is reduced by introducing collagenase or collagenase plus another proteinase into the tissue.
US20170087229 COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES  
A drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II...
US20170081654 METHOD FOR MONOMERIZING MATRIX METALLOPROTEINASE 7 (MMP-7) AGGREGATE  
A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a...
US20170072030 NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY  
The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a...
US20170072029 ENZYMATIC WOUND DEBRIDING COMPOSITIONS WITH ENHANCED ENZYMATIC ACTIVITY  
The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one...
US20170065686 Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV  
The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes...
US20170042984 METHODS FOR TREATMENT OF INCONTINENCE ASSOCIATED WITH SEXUAL ACTIVITY  
The invention provides compositions and methods for treating incontinence associated with sexual activity.
US20170042983 LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONS  
The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free...
US20170020997 METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN  
Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such as...
US20170014493 TREATMENT OF SOCIAL ANXIETY DISORDER, OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER USING BOTULINUM TOXIN  
Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount...
US20170000726 Compositions and Methods for the Delivery of Agents  
The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and...
US20160375112 Reducing Adverse Side Effects of a Compound by a Neurotoxin  
The present invention relates to methods and compositions for treating various side effects associated with the administration of one or more therapeutic compounds. In particular embodiments, the...
US20160369256 CATIONIC NEUROTOXINS  
The present invention provides an engineered clostridial toxin comprising at least one amino acid modification, wherein said at least one amino acid modification increases the isoelectric point...
US20160367539 CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS  
The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method includes...
US20160361429 Regulation of Specific Spinal Neurons Regulating Pain Transmission  
A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the...
US20160354450 Method for Treating Adhesive Capsulitis  
The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the...
US20160346367 THERMOSENSITIVE HYDROGEL COLLAGENASE FORMULATIONS  
It is an object of the present disclosure to provide a formulation for injectable collagenase which will have extended residence time for the drug at the therapeutic targeted area for the...
US20160339088 REDUCTION OF ADIPOSE TISSUE  
The amount of adipose tissue, including lipomas, at selected locations in the body is reduced by introducing collagenase or collagenase plus another proteinase into the tissue.
US20160331817 COMPOSITIONS AND METHODS FOR TREATING FIBROTIC MYOPATHY CONDITIONS USING COLLAGENASE  
Compositions and methods for treating fibrotic myopathy in a subject.
US20160296608 TREATMENT METHODS USING ATOXIC NEUROTOXIN DERIVATIVES  
The present invention relates to a treatment method. This method involves contacting a subject with an isolated, physiologically active, atoxic derivative of a Clostridial neurotoxin. Contacting...
US20160279384 Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs  
Methods and apparatus are provided for treatment of heart arrhythmia via renal neuromodulation. Such neuromodulation may effectuate irreversible electroporation or electrofusion, ablation,...
US20160279086 BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR  
The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
US20160279046 Methods for Treating Cellulite  
The invention relates to the discovery that collagenase injections are effective in dissolving and lysing the collagenase septa network in the skin that comprises cellulite. As such, the invention...
US20160274126 BIOMARKERS FOR THE DIAGNOSIS OF INTERSTITIAL CYSTITIS  
Disclosed are methods for the detection or diagnosis of a patient having symptoms of interstitial cystitis or overactive bladder. Also disclosed are HCN2 modulators and methods for the treatment...
US20160264955 COMPOSITIONS AND METHODS FOR INHIBITION OF MMP:MMP-SUBSTRATE INTERACTIONS  
The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site....
US20160263202 INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS  
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional...
US20160256531 TREATMENT OF POST-TRAUMATIC STRESS DISORDER USING BOTULINUM TOXIN A  
Methods are disclosed for treating post traumatic stress disorder (PTSD) in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator...
US20160256530 METHODS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF INDIVIDUALS HAVING OR LIKELY TO DEVELOP SHORT STATURE  
The instant disclosure relates to methods useful for the treatment or prevention of progressive growth failure in a subject in need thereof. The method may include the step of administering a...
US20160250302 Compositions and Methods for Safe Treatment of Rhinitis  
Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum...
US20160213758 METHODS AND APPARATUS FOR DELIVERING A THERAPEUTIC AGENT TO NASPHARYNGEAL MUCOSA TARGETS  
A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a...
US20160206711 Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact with the Corresponding Antigen  
A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the...
US20160193213 PHARMACEUTICAL FORMULATIONS OF XANTHINE OR XANTHINE DERIVATIVES  
Pharmaceutical compositions and methods for treating various diseases and pathologies, such as Dupuytren contracture, are described, the compositions comprising pentoxifylline and a...
US20160193161 TREATMENT AND PREVENTION OF STROKE AND OTHER NEUROLOGICAL DISORDERS  
Using high-throughput screening, in an oxygen-glucose deprivation (OGD) model, isoxsuprine hydrochloride was identified as a potent neuroprotective compound. In an animal middle artery occlusion...
US20160184413 FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT  
The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1...
US20160175410 SUSTAINED RELEASE POLOXAMER CONTAINING PHARMACEUTICAL COMPOSITIONS  
A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally...
US20160175409 INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS  
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional...
US20160175408 DIRECT APPLICATION SYSTEM AND METHOD FOR THE DELIVERY OF BIOACTIVE COMPOSITIONS AND FORMULATIONS  
The embodiments relate to improved skin quality, health and appearance using a new delivery method and certain bioactive compositions and formulations. The system incorporates microneedle delivery...
US20160175407 PROCESS FOR PREPARING A HIGHLY PURE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN AND USES THEREOF  
The present invention relates to a process for preparing a highly pure neurotoxic component of a botulinum toxin by cultivating clostridium botulinum under conditions that allow production of a...
US20160175379 COMBINATION THERAPY FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY  
The present technology provides methods of preventing or treating an ischemia-reperfusion injury, such as acute myocardial infarction injury, in a mammalian subject. The methods comprise...
US20160175243 NANOROD MATERIALS AND METHODS OF MAKING AND USING SAME  
The subject invention concerns nanorods, compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, the...
US20160168556 UNGLYCOSYLATED LYSOSTAPHIN VARIANT PROTEIN  
Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression...
US20160166703 Carrier Molecule Compositions and Related Methods  
A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one...
US20160166658 THERAPEUTIC INTERVENTION  
Provided are methods and materials for treating a neurological, behavioural, psychological, psychiatric, or personality disorder or syndrome in an individual, which disorder or syndrome is...
US20160158325 METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS INCLUDING DUPUYTREN'S DISEASE WITH ONE OR MORE SPECIFIC HUMAN MATRIX METALLOPROTEINASE AND A TNF ANTAGONIST  
The subject invention also provides a method of treating a subject afflicted with a fibroproliferative disorder comprising periodically administering to the patient an amount of one or more human...
US20160158176 COMPOSITIONS AND METHODS OF USING MODIFIED RELEASE SOLABEGRON FOR LOWER URINARY TRACT SYMPTOMS  
This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and...
US20160151468 Suture Line Administration Technique Using Botulinum Toxins  
The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a...
US20160151467 COMPOSITION COMPRISING FILLER AND BOTULINUM TOXIN FOR ALLEVIATING SKIN WRINKLES OR AGING OR TREATING NEUROMUSCULAR DISEASES  
The present invention discloses a composition comprising a filler and a botulinum toxin for improving skin wrinkles, preventing skin aging, or treating neuromuscular diseases. The composition...
US20160151444 METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY  
The invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an...

Matches 301 - 350 out of 409 < 1 2 3 4 5 6 7 8 9 >